RxDoctor Payments Data

Gregory Ballard, MD

Orthopaedic Surgery · Independence, MONPI 1942367040

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,400 of the $14,372 with a category attached, or 72.4%. Conformis, Inc. accounts for 79.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $11,421 and has fallen 98.4% since, to $185 in 2025.

$14,372in general payments, 2019–2025

Across 64 payments — averaging $224.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Conformis, Inc.$11K
  • Stryker$2K
  • Smith+Nephew$336
  • Johnson & Johnson$160
  • Davol Inc.$133
  • Amgen$128
  • plus $563 from 12 others
$378,667in ownership & investment interests, 2019–2025

Across 7 payments — averaging $54,095 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spinal Simplicity, LLC$379K

What the payments were for

  • Speaking & faculty fees$10,40072%
  • Travel & lodging$1,57811%
  • Food & beverage$2,39317%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,372 in reported general payments places this provider in the 70th percentile of 455 orthopaedic surgery providers in Missouri.

See all orthopaedic surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$266,875
Medicare patients
425
Services billed
5,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban118$34,185
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen157$2,417
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$1,437
Methylprednisolone189$1,250
Etodolac22$997
Tramadol Hcl120$470
Meloxicam143$468
Gabapentin47$229
Celecoxib32$147
Amoxicillin149$144
Clindamycin Hcl55$126
Levofloxacin32$85
Ondansetron Hcl14$77
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$64
Cyclobenzaprine Hcl12$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$160$34,185118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 455 orthopaedic surgery providers in Missouri.

Other orthopaedic surgery in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →